NeuroPaceNPCE +0.36%65 PB Ratio is 38.83 as of Jun. 29, 2026, which is 176% above its 10-year median of 14.05. GuruFocus rates NPCE with a GF Score™ of 65/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 786 Medical Devices & Instruments companies, NeuroPace ranks worse than 98.47% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), NeuroPace's share price is $16.54. NeuroPace's Book Value per Share for the quarter that ended in Mar. 2026 was $0.43. Hence, NeuroPace's PB Ratio of today is 38.83.
The historical rank and industry rank for NeuroPace's PB Ratio or its related term are showing as below:
NPCE'
s PB Ratio Range Over the Past 10 Years
Min: 0.78 Med: 14.05 Max: 55.21
Current: 38.44
During the past 7 years, NeuroPace's highest PB Ratio was 55.21. The lowest was 0.78. And the median was 14.05.
NPCE's PB Ratio is ranked worse than 98.47% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.015
vs NPCE: 38.44
During the past 12 months, NeuroPace's average Book Value Per Share Growth Rate was -42.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of NeuroPace was -25.80% per year. The lowest was -55.40% per year. And the median was -40.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NeuroPace PB Ratio Related Terms
NeuroPace PB Ratio Historical Data
* Premium members only.
The historical data trend for NeuroPace's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroPace's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's PB Ratio distribution charts can be found below:
* The bar in red indicates where NeuroPace's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NeuroPace's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NeuroPace (NPCE) has a PB Ratio of 38.83 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NeuroPace and its competitors. This is 176% above median its historical median of 14.05. Over the past decade, NeuroPace's PB Ratio has ranged from 0.78 to 55.21. According to the industry distribution chart, NeuroPace ranks #774 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 98.5%.
Is NeuroPace's PB Ratio too high?
NeuroPace's current PB Ratio of 38.83 is 176% above median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 55.21. The Medical Devices & Instruments industry median PB Ratio is 2.02. NeuroPace's value of 38.83 is 1827% above this industry median. Based on the distribution chart, NeuroPace ranks #774 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroPace has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's PB Ratio compare to CLPT and CTKB?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #774 out of 786 companies for PB Ratio. This places NeuroPace in the lower half of its industry. The industry median PB Ratio is 2.02. NeuroPace's value of 38.83 is 1827% above this benchmark. Historically, NeuroPace's own PB Ratio has ranged from 0.78 to 55.21 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 2.02, NeuroPace has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current PB Ratio of 38.83 is 1827% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current PB Ratio is 38.83, which is 176% above median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.54 — trading 45% above its estimated fair value. The current PB Ratio is 38.83, which is 176% above median its 10-year median of 14.05 and 1827% above the Medical Devices & Instruments industry median of 2.02. NeuroPace's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NeuroPace (NPCE), the current PB Ratio is 38.83 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $16.54 is trading 45% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
PB Ratio: 38.83 (176% above median its 10-year median of 14.05)
GF Value™: $11.41 vs. price of $16.54 (45% above fair value)
Industry Position: 1827% above the Medical Devices & Instruments median (#774 of 786)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score
Get the complete analysis for NPCE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
